^
    Apply
    A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer (NCT04586270)
    Phase 1
    Taiho Oncology, Inc.
    Recruiting
    Last update posted :
    06/05/2024
    Initiation :
    10/15/2020
    Primary completion :
    08/01/2024
    Completion :
    07/01/2027
    HER-2 • KRAS • PTEN • NF1
    |
    KRAS mutation • HR positive • KRAS G12C • HER-2 negative • KRAS G12D • NF1 mutation • KRAS G12 • HR positive + HER-2 negative
    |
    TAS0612